Nuchal translucency and first trimester biochemical markers for down syndrome screening: A cost-effectiveness analysis
Authors:
- Aaron B. CaugheyACAaron B. Caughey
- Miriam KuppermannMKMiriam Kuppermann
- Mary E. NortonMNMary E. Norton
- A.EUgene WashingtonAWA.EUgene Washington
- 1 November 2002
- journal article
- research article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 187 (5) , 1239-1245
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric populationUltrasound in Obstetrics & Gynecology, 1998
- UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestationThe Lancet, 1998
- Evaluation of first-trimester screening by fetal nuchal translucency and maternal agePrenatal Diagnosis, 1998
- First‐trimester screening for fetal aneuploidy: biochemistry and nuchal translucencyUltrasound in Obstetrics & Gynecology, 1997
- Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancyBJOG: An International Journal of Obstetrics & Gynaecology, 1994
- Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy.BMJ, 1992
- Maternal serum screening for Down's syndrome in early pregnancy.BMJ, 1988
- Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha‐fetoprotein levelBJOG: An International Journal of Obstetrics & Gynaecology, 1987
- An association between low maternal serum α-fetoprotein and fetal chromosomal abnormalitiesAmerican Journal of Obstetrics and Gynecology, 1984
- MATERNAL SERUM ALPHA-FETOPROTEIN MEASUREMENT: A SCREENING TEST FOR DOWN SYNDROMEThe Lancet, 1984